Old Web
English
Sign In
Acemap
>
authorDetail
>
Germaine Gaber
Germaine Gaber
Alexandria University
Internal medicine
Medicine
Bevacizumab
HER2 negative
Markov model
3
Papers
19
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Impact of p53, HIF1a, Ki-67, CA-9, and GLUT1 Expression on Treatment Outcomes in Locally Advanced Cervical Cancer Patients Treated With Definitive Chemoradiation Therapy.
2020
American Journal of Clinical Oncology
Germaine Gaber
Samar El Achy
Gehan Abd Elatti Khedr
Vamsi Parimi
I. Helenowksi
Eric D. Donnelly
Jonathan B. Strauss
Gayle E. Woloschak
Jian-Jun Wei
William Small
Tamer Refaat
Show All
Source
Cite
Save
Citations (2)
Cost-effectiveness analysis using a Markov model assessing the addition of bevacizumab to paclitaxel in HER2-negative metastatic breast cancer patients.
2017
Journal of Clinical Oncology
Tamer Refaat
Mehee Choi
Germaine Gaber
William Small
Krystyna Kiel
Show All
Source
Cite
Save
Citations (0)
Markov model and cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer.
2014
American Journal of Clinical Oncology
Tamer Refaat
Mehee Choi
Germaine Gaber
Krystyna Kiel
Minesh P. Mehta
William J. Gradishar
William Small
Show All
Source
Cite
Save
Citations (17)
1